SCIENTIFIC BACKGROUND

ABCB7, ABHD12, ADGRG1, AFG3L2, AHI1, AMACR, ARL13B, ARSA, ATCAY, ATM, ATP1A3, ATP8A2, ATXN10, BTD, CA8, CAPN1, CC2D2A, CEP290, CEP41, CLCN2, CLN5, CLN6, COQ8A, CP, CPLANE1, CSPP1, CYP27A1, DARS2, DLAT, DNAJC19, DNMT1, FLVCR1, GALC, GBA, GBA2, GJB1, GOSR2, INPP5E, KIAA0586, KIF1C, KIF7, MARS2, MRE11, MTPAP, NPC1, NPC2, NPHP1, OFD1, OPA1, OPA3, PANK2, PDE10A, PDE6D, PEX10, PEX2, PLA2G6, PNPLA6, POC1B, POLG, POLR3A, RPGRIP1L, SACS, SIL1, SLC17A5, SPG7, TCTN1, TCTN2, TCTN3, TMEM138, TMEM216, TMEM231, TMEM237, TMEM67, TTC21B, VAMP1, VLDLR, WFS1, ZNF423

Scientific background

  • 3-methylglutaconic aciduria, type III (OPA3, AR)
  • 3-Methylglutaconic aciduria, type V (DNAJC19, AR)
  • Alpha-methylacyl-CoA racemase deficiency (AMACR, AR)
  • Anemia, sideroblastic, with ataxia (ABCB7, XL)
  • Ataxia telangiectasia (ATM, AR)
  • Ataxia telangiectasia-like disease (MRE11, AR)
  • Ataxia, autosomal recessive (PEX10, AR)
  • Ataxia, cerebellar, Cayman type (ATCAY, AR)
  • Behr syndrome (OPA1, AR)
  • Biotinidase deficiency (BTD, AR)
  • Boucher-Neuhauser syndrome (PNPLA6, AR)
  • CAPOS syndrome (ATP1A3, AD)
  • Cerebellar ataxia (CP, AR)
  • Cerebellar ataxia and mental retardation (CA8, AR)
  • Cerebellar ataxia and mental retardation 4 (?) (ATP8A2, AR)
  • Cerebellar ataxia with spasticity (GBA2, AR)
  • Cerebellar ataxia, deafness and narcolepsy, autosomal dominant (DNMT1, AD)
  • Cerebellar hypoplasia and mental retardation (VLDLR, AR)
  • Cerebrotendinous xanthomatosis (CYP27A1, AR)
  • Charcot-Marie-Tooth neuropathy, X-dominant, 1 (GJB1, XLD)
  • Epilepsy, progressive, myoclonic 6 (GOSR2, AR)
  • Gaucher disease type III (GBA, AR)
  • Infantile-onset limb and orofacial dyskinesia (PDE10A, AR)
  • Joubert syndrome phenotype (POC1B, AR)
  • Joubert syndrome type 1 (INPP5E, AR)
  • Joubert syndrome type 10 (OFD1, XLR)
  • Joubert syndrome type 11 (TTC21B, AR)
  • Joubert syndrome type 12 (KIF7, AR)
  • Joubert syndrome type 13 (TCTN1, AR)
  • Joubert syndrome type 14 (TMEM237, AR)
  • Joubert syndrome type 15 (CEP41, AR)
  • Joubert syndrome type 16 (TMEM138, AR)
  • Joubert syndrome type 17 (CPLANE1, AR)
  • Joubert syndrome type 18 (TCTN3, AR)
  • Joubert syndrome type 19 (ZNF423, AR)
  • Joubert syndrome type 2 (TMEM216, AR)
  • Joubert syndrome type 20 (TMEM231, AR)
  • Joubert syndrome type 21 (CSPP1, AR)
  • Joubert syndrome type 22 (PDE6D, AR)
  • Joubert syndrome type 23 (KIAA0586, AR)
  • Joubert syndrome type 3 (AHI1, AR)
  • Joubert syndrome type 4 (NPHP1, AR)
  • Joubert syndrome type 5 (CEP290, AR)
  • Joubert syndrome type 6 (TMEM67, AR)
  • Joubert syndrome type 7 (RPGRIP1L, AR)
  • Joubert syndrome type 8 (ARL13B, AR)
  • Joubert syndrome type 9 (CC2D2A, AR)
  • Joubert/Meckel syndrome phenotype (TCTN2, AR)
  • Joubert/nephronophthisis phenotype (ATXN10, AR)
  • Krabbe disease (GALC, AR)
  • Leukoencephalopathy with ataxia (CLCN2, AR)
  • Leukoencephalopathy with brainstem and spinal involvement and lactate elevation (DARS2, AR)
  • Marinesco-Sjogren syndrome (SIL1, AR)
  • Metachromatic leukodystrophy (ARSA, AR)
  • Mitochondrial recessive ataxia syndrome (POLG, AR)
  • Neurodegeneration with iron accumulation in the brain (PLA2G6, AR)
  • Neurodegeneration with iron accumulation in brain 1 (PANK2, AR)
  • Neuronal ceroid lipofuscinosis 5 (CLN5, AR)
  • Neuronal ceroid lipofuscinosis 6 (CLN6, AR)
  • Niemann-Pick disease, type C1 (NPC1, AR)
  • Niemann-Pick disease, type C2 (NPC2, AR)
  • Peroxisome biogenesis defect 5B (PEX2, AR)
  • Polymicrogyria, bilateral frontoparietal (ADGRG1, AR)
  • Polyneuropathy, ataxia, hearing loss, retinitis pigmentosa and cataract (ABHD12, AR)
  • Posterior column ataxia with retinitis pigmentosa (FLVCR1, AR)
  • Primary coenzyme Q10 deficiency type 4 (COQ8A, AR)
  • Pyruvate dehydrogenase E2 deficiency (DLAT, AR)
  • Salla disease (SLC17A5, AR)
  • Spastic ataxia (POLR3A, AR)
  • Spastic ataxia (SPG7, AR)
  • Spastic ataxia type 1 (VAMP1, AD)
  • Spastic ataxia type 2 (KIF1C, AR)
  • Spastic ataxia type 3 (MARS2, AR)
  • Spastic ataxia type 4 (MTPAP, AR)
  • Spastic ataxia type 5 (AFG3L2, AR)
  • Spastic ataxia, Charlevoix-Saguena type (SACS, AR)
  • Spastic paraplegia 76 (CAPN1, AR)
  • Wolfram syndrome (WFS1, AR)

 

Disorders are inherited in an autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), or X-linked dominant (XLD) pattern.

 

For detailed information on ataxias and diagnostics, please visit our overview page ATAXIAS.

GENES

ABCB7, ABHD12, ADGRG1, AFG3L2, AHI1, AMACR, ARL13B, ARSA, ATCAY, ATM, ATP1A3, ATP8A2, ATXN10, BTD, CA8, CAPN1, CC2D2A, CEP290, CEP41, CLCN2, CLN5, CLN6, COQ8A, CP, CPLANE1, CSPP1, CYP27A1, DARS2, DLAT, DNAJC19, DNMT1, FLVCR1, GALC, GBA, GBA2, GJB1, GOSR2, INPP5E, KIAA0586, KIF1C, KIF7, MARS2, MRE11, MTPAP, NPC1, NPC2, NPHP1, OFD1, OPA1, OPA3, PANK2, PDE10A, PDE6D, PEX10, PEX2, PLA2G6, PNPLA6, POC1B, POLG, POLR3A, RPGRIP1L, SACS, SIL1, SLC17A5, SPG7, TCTN1, TCTN2, TCTN3, TMEM138, TMEM216, TMEM231, TMEM237, TMEM67, TTC21B, VAMP1, VLDLR, WFS1, ZNF423

ASSOCIATED TESTS

How to order

LATEST ARTICLES

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more

In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). ...

Read more

Genetics as we know and understand it today has been shaped, over decades, by the work of many dedicated scientists around the world, and they all de...

Read more